Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
NCT ID: NCT03355235
Last Updated: 2020-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2017-10-20
2019-08-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
NCT05556928
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
NCT01890486
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
NCT03992352
Prospective Observational Clinical Study on Changes in Cognitive Levels in Elderly Patients Before and After Hematopoietic Stem Cell Transplantation
NCT06484049
The Patients' Experience After Stem Cell Transplant
NCT03454568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cognitive assessment using standardized tools
cognitive assessment using standardized tools pre and post transplant.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who will undergo pre-transplant evaluation with intentions to proceed to autologous stem cell transplant after stem cell collection.
* Patients willing and able to understand and sign an informed consent form
* Patients 18 yrs of age or older
Exclusion Criteria
* Patients who are considered unable to perform study evaluations at the investigator's discretion.
* Patients who are unable to read. (If patients require reading glasses, they must be worn at time of test.)
* Patients who do not proceed to stem cell transplant within 60 days of stem cell collection will be excluded from study.
* Patients who receive more than one cycle of chemotherapy between the time of stem cell collection and transplant will be excluded from study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cesar Rodriguez, MD
Role: STUDY_CHAIR
Wake Forest University Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCCWFU 02117
Identifier Type: OTHER
Identifier Source: secondary_id
IRB00045767
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.